Population Pharmacokinetics of Imatinib in CML Patients in Iran

Status Terminated

Clinical Trial Summary

The purpose of this study is to determine population Pharmacokinetics and differences and variation of pharmacokinetics parameters of Imatinib as a tyrosine kinase inhibitor in treatment of chronic myeloid leukemia patients in Iranian population.

Clinical Trial Description

patients with chronic myeloid leukemia who receive Imatinib as treatment in Iran entered in this study then population pharmacokinetics parameters is determined. ;

Study Design

Observational Model: Ecologic or Community, Time Perspective: Prospective

Related Conditions & MeSH terms

Chronic Myelogenous Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid

Clinical Trial Details

NCT number	NCT02146846
Study type	Observational
Source	Kerman University of Medical Sciences
Contact
Status	Terminated
Phase	N/A
Start date	October 2012
Completion date	July 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05088356` - Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft	Phase 1
Recruiting	`NCT04904588` - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide	Phase 2
Completed	`NCT02592447` - Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) Intervention	N/A
Withdrawn	`NCT04282174` - CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies	Phase 2
Terminated	`NCT01397734` - Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)	Phase 1
Completed	`NCT00975975` - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer	Phase 2
Withdrawn	`NCT01011998` - A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)	Phase 2
Completed	`NCT00378534` - Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants	Phase 2
Completed	`NCT00098033` - Investigation of Clofarabine in Acute Leukemias	Phase 2
Terminated	`NCT00852709` - Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias	Phase 1
Completed	`NCT02581007` - Reduced Intensity Conditioning Transplant Using Haploidentical Donors	Phase 2
Terminated	`NCT03547154` - Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)	Phase 2/Phase 3
Terminated	`NCT02709083` - Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia	Phase 2
Terminated	`NCT02145039` - Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases	N/A
Active, not recruiting	`NCT01036009` - A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies	Phase 2
Completed	`NCT00990587` - Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy	Phase 1
Terminated	`NCT00594308` - In-Vivo Activated T-Cell Depletion to Prevent GVHD	N/A
Terminated	`NCT00500006` - A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)	Phase 1
Completed	`NCT00493181` - Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients	Phase 2
Completed	`NCT00081926` - Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia	Phase 4